← Eichor
Study identifier: NCT05691244 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Condition: Acute Ischemic Stroke · Cerebral Stroke  ·  Sponsor: Pharmazz, Inc.

PhasePhase 3
Planned participants514
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair in later stages of stroke. Several trials have been conducted and are in progress using different pharmacological agents, but none of the studies involve the stimulation of ETB receptors to treat cerebral ischemic stroke. Sovateltide (IRL-1620, PMZ-1620) has been effective in animal models of cerebral ischemic stroke. Its safety and tolerability have been demonstrated in a human phase I study with 7 subjects. Clinical phase II and III results indicate that sovateltide is a novel, first-in-class, highly effective drug candidate for treating cerebral ischemic stroke. Safety and significant efficacy in improving the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin scale (mRS), and Barthel index (BI) obtained in phase II and III studies in patients with cerebral ischemic stroke in India are convincing and encouraged us to investigate its safety and efficacy in cerebral ischemic stroke patients in the United States. Therefore, the plan is to conduct a phase III clinical study to evaluate the safety and efficacy of sovateltide therapy along with standard of care in patients of acute ischemic stroke.

This description comes directly from the study's public registry record.

Talk to the study team

Anil Gulati, MD, PhD  ·  6307806087  ·  anil.gulati@pharmazz.com

Neil Marwah, MD  ·  6307806087  ·  neil.marwah@pharmazz.com

Always discuss trial participation with your own doctor first.

Locations (54)

The University of Arizona - College of MedicineTucson, Arizona, United StatesRecruiting
Mercy Medical GroupCarmichael, California, United StatesRecruiting
St. John's Regional Medical CenterOxnard, California, United StatesRecruiting
Sarasota Memorial HospitalSarasota, Florida, United StatesRecruiting
Wellstar Kennestone HospitalMarietta, Georgia, United StatesRecruiting
SSM Health NeurosciencesBridgeton, Missouri, United StatesRecruiting
Hackensack University Medical Center at ParamusParamus, New Jersey, United StatesRecruiting
Guilford Neurologic Associates IncGreensboro, North Carolina, United StatesRecruiting
OSU Wexner Medical CenterColumbus, Ohio, United StatesRecruiting
Penn State Health Milton S. Hershey Medical CenterHershey, Pennsylvania, United StatesRecruiting
UPMC Presbyterian HospitalPittsburgh, Pennsylvania, United StatesRecruiting
CHI Memorial Neuroscience InstituteChattanooga, Tennessee, United StatesRecruiting

+ 42 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05691244